• +55 (48) 3261-2856
  • contato@cienp.org.br

Mês: janeiro 2018

Upcoming market catalysts in Q1 2018

Potential market catalysts in the first quarter of 2018 include important top-line clinical trial results for rigerimod (developed by ImmuPharma and SymBio) for systemic lupus… Para acessar a publicação na íntegra clique aqui Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | JANUARY 2018 …

NEWS & ANALYSIS

First in vivo gene-editing drugs enter the clinic Sangamo Therapeutics has started dosing patients with gene-editing drugs that are administered directly into the blood. Para acessar a publicação na íntegra clique aqui Click here to original publication. Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | JANUARY 2018…